How MEG3 gene deletion linked to nickel exposure may lead to lung cancer
MEG3 deletion drives lung tumorigenesis due to environmental nickel exposure
This study is looking at how a specific gene called MEG3 might be involved in lung cancer caused by exposure to nickel in the environment, and it aims to find new ways to prevent or treat lung cancer for people affected by these factors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10778601 on NIH RePORTER |
What this research studies
This research investigates the role of the MEG3 gene in lung cancer development due to exposure to environmental nickel. It utilizes advanced sequencing techniques to analyze how nickel affects the expression of long noncoding RNAs in human bronchial cells. By understanding the mechanisms of gene regulation and transformation in these cells, the study aims to identify potential pathways that lead to lung tumorigenesis. Patients may benefit from insights that could lead to new prevention or treatment strategies for lung cancer linked to environmental factors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of environmental nickel exposure or those at risk for lung cancer.
Not a fit: Patients who do not have a history of nickel exposure or lung cancer risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide critical insights into lung cancer prevention and treatment related to environmental exposures.
How similar studies have performed: Previous studies have shown associations between environmental carcinogens and cancer, but this specific focus on MEG3 and nickel exposure is a novel approach.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Costa, Max — New York University School of Medicine
- Study coordinator: Costa, Max
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.